UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...

UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The ...

AbbVie (ABBV) stock is in focus as UCB's Bimzelx beats the company's immunology blockbuster Skyrizi in head-to-head trial for ...

CNW/ - UCB, a global biopharmaceutical company committed to improving the lives of people with severe diseases, announced the ...

ATLANTA (AP) — Belgian pharmaceutical company UCB announced Tuesday that it would invest $2 billion to build a drug-making plant in suburban Atlanta. The rapidly growing drugmaker said the plant, ...

The Belgian pharma company is paying $2 billion upfront for Candid's pipeline of T-cell engagers targeting autoimmune ...

UCB, a global biopharmaceutical company, today announced Week 16 data from the BE BOLD trial demonstrating superior ACR50 joint outcomes at Week 16 for BIMZELX® (bimekizumab-bkzx) versus SKYRIZI® ...

PARIS, May 3 (Reuters) - Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday. UCB will pay $2 ...

UCB is adding a big piece to its immunology pipeline with a multi-billion dollar deal to buy Candid Therapeutics, a clinical-stage biotech company developing therapies in a promising but competitive ...

UCB S.A. company facts, information and financial ratios from MarketWatch.